{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:33:56Z","timestamp":1793064836472,"version":"4.5.0"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41569-025-01220-4","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:50:21Z","timestamp":1759755021000},"page":"219-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The global cardiovascular\u2013liver\u2013metabolic syndemic: epidemiology, trends and challenges"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-0430","authenticated-orcid":false,"given":"Nicholas W. S.","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaycie","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-7450","authenticated-orcid":false,"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1220_CR1","unstructured":"GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 403, 2204\u20132256 (2024)."},{"key":"1220_CR2","unstructured":"Cardiovascular diseases (CVDs). World Health Organization https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds) (2021)."},{"key":"1220_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.971484","volume":"13","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front. Genet. 13, 971484 (2022).","journal-title":"Front. Genet."},{"key":"1220_CR4","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","volume":"73","author":"EP Stahl","year":"2019","unstructured":"Stahl, E. P. et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 948\u2013963 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1220_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"1220_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","volume":"39","author":"BK Lauridsen","year":"2018","unstructured":"Lauridsen, B. K. et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279,013 individuals. Eur. Heart J. 39, 385\u2013393 (2018).","journal-title":"Eur. Heart J."},{"key":"1220_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","volume":"151","author":"NWS Chew","year":"2025","unstructured":"Chew, N. W. S. et al. Cardiovascular\u2013liver\u2013metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach. Circulation 151, 98\u2013119 (2025).","journal-title":"Circulation"},{"key":"1220_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1220_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","volume":"122","author":"V Lekakis","year":"2024","unstructured":"Lekakis, V. & Papatheodoridis, G. V. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur. J. Intern. Med. 122, 3\u201310 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"1220_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11886-024-02025-6","volume":"26","author":"ECZ Lee","year":"2024","unstructured":"Lee, E. C. Z. et al. The global epidemic of metabolic fatty liver disease. Curr. Cardiol. Rep. 26, 199\u2013210 (2024).","journal-title":"Curr. Cardiol. Rep."},{"key":"1220_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","volume":"35","author":"NWS Chew","year":"2023","unstructured":"Chew, N. W. S. et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 35, 414\u2013428.e413 (2023).","journal-title":"Cell Metab."},{"key":"1220_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"W-K Chan","year":"2023","unstructured":"Chan, W.-K. et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J. Obes. Metab. Synd. 32, 197\u2013213 (2023).","journal-title":"J. Obes. Metab. Synd."},{"key":"1220_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"1220_CR14","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41591-024-03223-z","volume":"30","author":"F Zannad","year":"2024","unstructured":"Zannad, F., Sanyal, A. J., Butler, J., Miller, V. & Harrison, S. A. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat. Med. 30, 2423\u20132431 (2024).","journal-title":"Nat. Med."},{"key":"1220_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m, H., Shang, Y., Hegmar, H. & Nasr, P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol. Hepatol. 9, 944\u2013956 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1220_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang, D. Q. et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat. Rev. Dis. Prim. 11, 14 (2025).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1220_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(18)32822-8","volume":"393","author":"BA Swinburn","year":"2019","unstructured":"Swinburn, B. A. et al. The global syndemic of obesity, undernutrition, and climate change: the Lancet Commission report. Lancet 393, 791\u2013846 (2019).","journal-title":"Lancet"},{"key":"1220_CR18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular\u2013kidney\u2013metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"1220_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/ndt\/gfae086","volume":"39","author":"C Zoccali","year":"2024","unstructured":"Zoccali, C. & Zannad, F. Refocusing cardio-renal problems: the cardiovascular\u2013kidney\u2013metabolic syndrome and the chronic cardiovascular\u2013kidney disorder. Nephrol. Dial. Transpl. 39, 1378\u20131380 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1220_CR20","doi-asserted-by":"crossref","unstructured":"Chew, N. W. S., Muthiah, M. D. & Sanyal, A. J. in Cardiovascular Endocrinology and Metabolism (eds Krentz, A. J. & Chilton, R. J.) 137\u2013173 (Academic Press, 2023).","DOI":"10.1016\/B978-0-323-99991-5.00003-6"},{"key":"1220_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73, 691\u2013702 (2024).","journal-title":"Gut"},{"key":"1220_CR22","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","volume":"79","author":"A Roca-Fernandez","year":"2023","unstructured":"Roca-Fernandez, A. et al. Liver disease is a significant risk factor for cardiovascular outcomes \u2014 a UK Biobank study. J. Hepatol. 79, 1085\u20131095 (2023).","journal-title":"J. Hepatol."},{"key":"1220_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/ehjqcco\/qcad059","volume":"10","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Risk of incident cardiovascular disease among patients with gastrointestinal disorder: a prospective cohort study of 330,751 individuals. Eur. Heart J. Qual. Care Clin. Outcomes 10, 357\u2013365 (2024).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"1220_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee, H. H. et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 73, 533\u2013540 (2024).","journal-title":"Gut"},{"key":"1220_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","volume":"21","author":"R P\u00e1lsson","year":"2014","unstructured":"P\u00e1lsson, R. & Patel, U. D. Cardiovascular complications of diabetic kidney disease. Adv. Chronic Kidney Dis. 21, 273\u2013280 (2014).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"1220_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jchf.2020.09.006","volume":"9","author":"M Khayyat-Kholghi","year":"2021","unstructured":"Khayyat-Kholghi, M., Oparil, S., Davis, B. R. & Tereshchenko, L. G. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. JACC Heart Fail. 9, 100\u2013111 (2021).","journal-title":"JACC Heart Fail."},{"key":"1220_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1055\/s-0041-1730927","volume":"41","author":"M Arrese","year":"2021","unstructured":"Arrese, M. et al. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin. Liver Dis. 41, 421\u2013434 (2021).","journal-title":"Semin. Liver Dis."},{"key":"1220_CR28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/17512433.2023.2259306","volume":"16","author":"A Lonardo","year":"2023","unstructured":"Lonardo, A. The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers. Expert. Rev. Clin. Pharmacol. 16, 891\u2013911 (2023).","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"1220_CR29","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy, V. et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3624\u20133633 (2024).","journal-title":"Nat. Med."},{"key":"1220_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan, N., Yki-J\u00e4rvinen, H. & Neuschwander-Tetri, B. A. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 13, 134\u2013148 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1220_CR31","first-page":"226","volume":"22","author":"N Stefan","year":"2025","unstructured":"Stefan, N. & Targher, G. Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine. Nat. Rev. Gastroenterol. Hepatol. 22, 226\u2013227 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR32","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.2215\/CJN.02180311","volume":"6","author":"G Thomas","year":"2011","unstructured":"Thomas, G. et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 6, 2364\u20132373 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1220_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2, 901\u2013910 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1220_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaneurol.2015.4899","volume":"73","author":"TP Ng","year":"2016","unstructured":"Ng, T. P. et al. Metabolic syndrome and the risk of mild cognitive impairment and progression to dementia: follow-up of the Singapore Longitudinal Ageing Study cohort. JAMA Neurol. 73, 456\u2013463 (2016).","journal-title":"JAMA Neurol."},{"key":"1220_CR35","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1161\/STROKEAHA.117.017709","volume":"48","author":"E Ben Assayag","year":"2017","unstructured":"Ben Assayag, E. et al. Type 2 diabetes mellitus and impaired renal function are associated with brain alterations and poststroke cognitive decline. Stroke 48, 2368\u20132374 (2017).","journal-title":"Stroke"},{"key":"1220_CR36","first-page":"207","volume":"60","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci, E. et al. Diabetes and cancer: a consensus report. CA Cancer J. Clin. 60, 207\u2013221 (2010).","journal-title":"CA Cancer J. Clin."},{"key":"1220_CR37","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.2337\/dc12-0336","volume":"35","author":"K Esposito","year":"2012","unstructured":"Esposito, K., Chiodini, P., Colao, A., Lenzi, A. & Giugliano, D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35, 2402\u20132411 (2012).","journal-title":"Diabetes Care"},{"key":"1220_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1055\/s-0042-1757712","volume":"42","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. NAFLD in cardiovascular diseases: a contributor or comorbidity? Semin. Liver Dis. 42, 465\u2013474 (2022).","journal-title":"Semin. Liver Dis."},{"key":"1220_CR39","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","volume":"81","author":"A Ahmed","year":"2024","unstructured":"Ahmed, A., Cule, M., Bell, J. D., Sattar, N. & Yaghootkar, H. Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer. J. Hepatol. 81, 921\u2013929 (2024).","journal-title":"J. Hepatol."},{"key":"1220_CR40","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi, O. et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3614\u20133623 (2024).","journal-title":"Nat. Med."},{"key":"1220_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mayocp.2021.08.021","volume":"97","author":"S Tejani","year":"2022","unstructured":"Tejani, S. et al. Cardiometabolic health outcomes associated with discordant visceral and liver fat phenotypes: insights from the Dallas Heart Study and UK Biobank. Mayo Clin. Proc. 97, 225\u2013237 (2022).","journal-title":"Mayo Clin. Proc."},{"key":"1220_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155402","volume":"141","author":"B Chong","year":"2023","unstructured":"Chong, B. et al. The global syndemic of metabolic diseases in the young adult population: a consortium of trends and projections from the global burden of disease 2000\u20132019. Metabolism 141, 155402 (2023).","journal-title":"Metabolism"},{"key":"1220_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clnu.2024.11.016","volume":"43","author":"XD Zhou","year":"2024","unstructured":"Zhou, X. D. et al. Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15\u201339, 1990\u20132021. Clin. Nutr. 43, 391\u2013404 (2024).","journal-title":"Clin. Nutr."},{"key":"1220_CR44","unstructured":"Waters, H. & Marlon, G. America\u2019s obesity crisis: the health and economic costs of excess weight. Milken Institute https:\/\/milkeninstitute.org\/sites\/default\/files\/reports-pdf\/Mi-Americas-Obesity-Crisis-WEB.pdf (2018)."},{"key":"1220_CR45","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"G Whitlock","year":"2009","unstructured":"Whitlock, G. et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373, 1083\u20131096 (2009).","journal-title":"Lancet"},{"key":"1220_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60142-y","volume":"10","author":"R Salehidoost","year":"2020","unstructured":"Salehidoost, R., Mansouri, A., Amini, M., Aminorroaya Yamini, S. & Aminorroaya, A. Diabetes and all-cause mortality, a 18-year follow-up study. Sci. Rep. 10, 3183 (2020).","journal-title":"Sci. Rep."},{"key":"1220_CR47","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/hep.30094","volume":"68","author":"AM Allen","year":"2018","unstructured":"Allen, A. M., Van Houten, H. K., Sangaralingham, L. R., Talwalkar, J. A. & McCoy, R. G. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. Hepatology 68, 2230\u20132238 (2018).","journal-title":"Hepatology"},{"key":"1220_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036518","volume":"13","author":"AK April-Sanders","year":"2024","unstructured":"April-Sanders, A. K. Integrating social determinants of health in the management of cardiovascular\u2013kidney\u2013metabolic syndrome. J. Am. Heart Assoc. 13, e036518 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1220_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Le","year":"2022","unstructured":"Le, M. H. et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach. Clin. Mol. Hepatol. 28, 841\u2013850 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"1220_CR50","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J. Hepatol. 69, 896\u2013904 (2018).","journal-title":"J. Hepatol."},{"key":"1220_CR51","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 22, 1999\u20132010.e1998 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1220_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek, J. et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 8, 20\u201330 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1220_CR53","doi-asserted-by":"publisher","first-page":"glae011","DOI":"10.1093\/gerona\/glae011","volume":"79","author":"D Clayton-Chubb","year":"2024","unstructured":"Clayton-Chubb, D. et al. Late-life metabolic dysfunction-associated steatotic liver disease and its association with physical disability and dementia. J. Gerontol. A 79, glae011 (2024).","journal-title":"J. Gerontol. A"},{"key":"1220_CR54","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/hep.32228","volume":"75","author":"JM Paik","year":"2022","unstructured":"Paik, J. M. et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology 75, 1204\u20131217 (2022).","journal-title":"Hepatology"},{"key":"1220_CR55","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","volume":"20","author":"EJ Lee","year":"2024","unstructured":"Lee, E. J. et al. Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J. Pediatr. 20, 569\u2013580 (2024).","journal-title":"World J. Pediatr."},{"key":"1220_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dsi23-0010","volume":"37","author":"ZM Younossi","year":"2024","unstructured":"Younossi, Z. M. & Henry, L. Understanding the burden of nonalcoholic fatty liver disease: time for action. Diabetes Spectr. 37, 9\u201319 (2024).","journal-title":"Diabetes Spectr."},{"key":"1220_CR57","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30946","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba, R. & Adams, L. A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70, 1885\u20131888 (2019).","journal-title":"Hepatology"},{"key":"1220_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411\u2013428 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/a-2289-2298","volume":"44","author":"T Kodama","year":"2024","unstructured":"Kodama, T. & Takehara, T. Molecular genealogy of metabolic-associated hepatocellular carcinoma. Semin. Liver Dis. 44, 147\u2013158 (2024).","journal-title":"Semin. Liver Dis."},{"key":"1220_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/srep33386","volume":"6","author":"S Wu","year":"2016","unstructured":"Wu, S. et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci. Rep. 6, 33386 (2016).","journal-title":"Sci. Rep."},{"key":"1220_CR61","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","volume":"24","author":"C Anania","year":"2018","unstructured":"Anania, C., Perla, F. M., Olivero, F., Pacifico, L. & Chiesa, C. Mediterranean diet and nonalcoholic fatty liver disease. World J. Gastroenterol. 24, 2083\u20132094 (2018).","journal-title":"World J. Gastroenterol."},{"key":"1220_CR62","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao, L., Targher, G., Byrne, C. D., Cao, Y. Y. & Zheng, M. H. Current status and future trends of the global burden of MASLD. Trends Endocrinol. Metab. 35, 697\u2013707 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"1220_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jhep.2024.08.011","volume":"82","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M. et al. Association of food insecurity with MASLD prevalence and liver-related mortality. J. Hepatol. 82, 203\u2013210 (2025).","journal-title":"J. Hepatol."},{"key":"1220_CR64","doi-asserted-by":"publisher","first-page":"13647","DOI":"10.3390\/ijerph192013647","volume":"19","author":"M Lonnie","year":"2022","unstructured":"Lonnie, M., Wadolowska, L., Morze, J. & Bandurska-Stankiewicz, E. Associations of dietary\u2013lifestyle patterns with obesity and metabolic health: two-year changes in MeDiSH(\u00ae) study cohort. Int. J. Env. Res. Public Health 19, 13647 (2022).","journal-title":"Int. J. Env. Res. Public Health"},{"key":"1220_CR65","unstructured":"Obesity and overweight. World Health Organization https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2024)."},{"key":"1220_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Global burden of metabolic diseases, 1990\u20132021. Metabolism 160, 155999 (2024).","journal-title":"Metabolism"},{"key":"1220_CR67","doi-asserted-by":"publisher","first-page":"102848","DOI":"10.1016\/j.eclinm.2024.102848","volume":"76","author":"X-D Zhou","year":"2024","unstructured":"Zhou, X.-D. et al. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021. eClinicalMedicine 76, 102848 (2024).","journal-title":"eClinicalMedicine"},{"key":"1220_CR68","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"M Ng","year":"2025","unstructured":"Ng, M. et al. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405, 813\u2013838 (2025).","journal-title":"Lancet"},{"key":"1220_CR69","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(19)30179-2","volume":"7","author":"F Azizi","year":"2019","unstructured":"Azizi, F. et al. Metabolic health in the Middle East and north Africa. Lancet Diabetes Endocrinol. 7, 866\u2013879 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1220_CR70","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps, N. H. et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403, 1027\u20131050 (2024).","journal-title":"Lancet"},{"key":"1220_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101850","volume":"57","author":"B Chong","year":"2023","unstructured":"Chong, B. et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019. eClinicalMedicine 57, 101850 (2023).","journal-title":"eClinicalMedicine"},{"key":"1220_CR72","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","volume":"19","author":"A Lonardo","year":"2020","unstructured":"Lonardo, A., Mantovani, A., Lugari, S. & Targher, G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann. Hepatol. 19, 359\u2013366 (2020).","journal-title":"Ann. Hepatol."},{"key":"1220_CR73","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41574-024-01008-5","volume":"20","author":"MB Schulze","year":"2024","unstructured":"Schulze, M. B. & Stefan, N. Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. Nat. Rev. Endocrinol. 20, 633\u2013646 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1220_CR74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","volume":"91","author":"ZM Younossi","year":"2012","unstructured":"Younossi, Z. M. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 91, 319\u2013327 (2012).","journal-title":"Medicine"},{"key":"1220_CR75","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.amjcard.2022.05.018","volume":"178","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. Prognostically distinct phenotypes of metabolic health beyond obesity in aortic stenosis. Am. J. Cardiol. 178, 112\u2013118 (2022).","journal-title":"Am. J. Cardiol."},{"key":"1220_CR76","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jacc.2011.04.047","volume":"58","author":"C Voulgari","year":"2011","unstructured":"Voulgari, C. et al. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J. Am. Coll. Cardiol. 58, 1343\u20131350 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1220_CR77","unstructured":"GBD results. Institute for Health Metrics and Evaluation (IHME) https:\/\/www.healthdata.org\/data-tools-practices\/interactive-visuals\/gbd-results (2024)."},{"key":"1220_CR78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"1220_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1220_CR80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jacc.2025.04.061","volume":"86","author":"B Chong","year":"2025","unstructured":"Chong, B. et al. The global syndemic of modifiable cardiovascular risk factors projected from 2025 to 2050. J. Am. Coll. Cardiol. 86, 165\u2013177 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1220_CR81","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0140-6736(24)00932-2","volume":"403","author":"M Zhou","year":"2024","unstructured":"Zhou, M. & Shen, H. Forecasting the global burden of disease to 2050. Lancet 403, 1961\u20131963 (2024).","journal-title":"Lancet"},{"key":"1220_CR82","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jgh.13264","volume":"31","author":"S Ballestri","year":"2016","unstructured":"Ballestri, S. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31, 936\u2013944 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1220_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1050049","volume":"14","author":"Y Tan","year":"2023","unstructured":"Tan, Y., He, Q. & Chan, K. H. K. Identification of shared genetic architecture between non-alcoholic fatty liver disease and type 2 diabetes: a genome-wide analysis. Front. Endocrinol. 14, 1050049 (2023).","journal-title":"Front. Endocrinol."},{"key":"1220_CR84","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco, R. et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 44, 399\u2013406 (2021).","journal-title":"Diabetes Care"},{"key":"1220_CR85","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera, V. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 78, 471\u2013478 (2023).","journal-title":"J. Hepatol."},{"key":"1220_CR86","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793\u2013801 (2019).","journal-title":"J. Hepatol."},{"key":"1220_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72795-0","volume":"14","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021. Sci. Rep. 14, 22232 (2024).","journal-title":"Sci. Rep."},{"key":"1220_CR88","doi-asserted-by":"publisher","unstructured":"Qi, X., Li, J., Caussy, C., Teng, G. J. & Loomba, R. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000000913 (2024).","DOI":"10.1097\/HEP.0000000000000913"},{"key":"1220_CR89","unstructured":"Global burden of disease 2021: findings from the GBD 2021 study. Institute for Health Metrics and Evaluation (IHME) https:\/\/www.healthdata.org\/research-analysis\/library\/global-burden-disease-2021-findings-gbd-2021-study (2024)."},{"key":"1220_CR90","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.jacc.2022.11.001","volume":"80","author":"M Lindstrom","year":"2022","unstructured":"Lindstrom, M. et al. Global burden of cardiovascular diseases and risks collaboration, 1990\u20132021. J. Am. Coll. Cardiol. 80, 2372\u20132425 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1220_CR91","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","volume":"32","author":"B Chong","year":"2025","unstructured":"Chong, B. et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur. J. Prev. Cardiol. 32, 1001\u20131015 (2025).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1220_CR92","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.lanwpc.2024.101138","volume":"49","author":"RSJ Goh","year":"2024","unstructured":"Goh, R. S. J. et al. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions. Lancet Regional Health Western Pacif. 49, 101138 (2024).","journal-title":"Lancet Regional Health Western Pacif."},{"key":"1220_CR93","doi-asserted-by":"publisher","first-page":"100803","DOI":"10.1016\/j.lanwpc.2023.100803","volume":"37","author":"NW Chew","year":"2023","unstructured":"Chew, N. W. et al. Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort. Lancet Regional Health Western Pacif. 37, 100803 (2023).","journal-title":"Lancet Regional Health Western Pacif."},{"key":"1220_CR94","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"JZK Toh","year":"2022","unstructured":"Toh, J. Z. K. et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 20, 2462\u20132473.e2410 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1220_CR95","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030269","volume":"12","author":"D Miyamori","year":"2023","unstructured":"Miyamori, D. et al. Coexistence of metabolic dysfunction-associated fatty liver disease and chronic kidney disease is a more potent risk factor for ischemic heart disease. J. Am. Heart Assoc. 12, e030269 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"1220_CR96","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1111\/dom.15660","volume":"26","author":"G Kong","year":"2024","unstructured":"Kong, G. et al. The prognostic value of metabolic dysfunction-associated steatotic liver disease in acute myocardial infarction: a propensity score-matched analysis. Diabetes Obes. Metab. 26, 3328\u20133338 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1220_CR97","volume":"12","author":"MA Khan","year":"2020","unstructured":"Khan, M. A. et al. Global epidemiology of ischemic heart disease: results from the Global Burden of Disease Study. Cureus 12, e9349 (2020).","journal-title":"Cureus"},{"key":"1220_CR98","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/2047487314525529","volume":"22","author":"A Scuteri","year":"2020","unstructured":"Scuteri, A. et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur. J. Prev. Cardiol. 22, 486\u2013491 (2020).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1220_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.812030","volume":"9","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. Association between non-alcoholic fatty liver disease and risk of stroke: a systematic review and meta-analysis. Front. Cardiovasc. Med. 9, 812030 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"1220_CR100","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.3390\/cimb46070399","volume":"46","author":"K Ferenc","year":"2024","unstructured":"Ferenc, K., Jarmakiewicz-Czaja, S., Sokal-Dembowska, A., Stasik, K. & Filip, R. Common denominator of MASLD and some non-communicable diseases. Curr. Issues Mol. Biol. 46, 6690\u20136709 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"key":"1220_CR101","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","volume":"20","author":"VL Feigin","year":"2021","unstructured":"Feigin, V. L. et al. Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 20, 795\u2013820 (2021).","journal-title":"Lancet Neurol."},{"key":"1220_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1047129","volume":"9","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: a systematic analysis of the Global Burden of Disease Study 2019. Front. Nutr. 9, 1047129 (2022).","journal-title":"Front. Nutr."},{"key":"1220_CR103","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S0140-6736(20)31374-X","volume":"396","author":"JD Pandian","year":"2020","unstructured":"Pandian, J. D. et al. Stroke systems of care in low-income and middle-income countries: challenges and opportunities. Lancet 396, 1443\u20131451 (2020).","journal-title":"Lancet"},{"key":"1220_CR104","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000336862","volume":"38","author":"MJ Cossi","year":"2012","unstructured":"Cossi, M. J., Preux, P. M., Chabriat, H., Gobron, C. & Houinato, D. Knowledge of stroke among an urban population in Cotonou (Benin). Neuroepidemiology 38, 172\u2013178 (2012).","journal-title":"Neuroepidemiology"},{"key":"1220_CR105","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(16)30506-2","volume":"388","author":"MJ O\u2019Donnell","year":"2016","unstructured":"O\u2019Donnell, M. J. et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case\u2013control study. Lancet 388, 761\u2013775 (2016).","journal-title":"Lancet"},{"key":"1220_CR106","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S2214-109X(18)30002-0","volume":"6","author":"MO Owolabi","year":"2018","unstructured":"Owolabi, M. O. et al. Dominant modifiable risk factors for stroke in Ghana and Nigeria (SIREN): a case\u2013control study. Lancet Glob. Health 6, e436\u2013e446 (2018).","journal-title":"Lancet Glob. Health"},{"key":"1220_CR107","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2022","unstructured":"Savarese, G. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Res. 118, 3272\u20133287 (2022).","journal-title":"Cardiovascular Res."},{"key":"1220_CR108","doi-asserted-by":"publisher","first-page":"ehad655.876","DOI":"10.1093\/eurheartj\/ehad655.876","volume":"44","author":"GA Roth","year":"2023","unstructured":"Roth, G. A. et al. The global burden of heart failure: a systematic analysis for the Global Burden of Disease Study 2021. Eur. Heart J. 44, ehad655.876 (2023).","journal-title":"Eur. Heart J."},{"key":"1220_CR109","doi-asserted-by":"publisher","unstructured":"Mantovani, A. et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut https:\/\/doi.org\/10.1136\/gutjnl-2022-327672 (2022).","DOI":"10.1136\/gutjnl-2022-327672"},{"key":"1220_CR110","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","volume":"28","author":"NL Bragazzi","year":"2021","unstructured":"Bragazzi, N. L. et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur. J. Prev. Cardiol. 28, 1682\u20131690 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1220_CR111","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/eurjpc\/zwac044","volume":"29","author":"M Lv","year":"2022","unstructured":"Lv, M. et al. Global burden of rheumatic heart disease and its association with socioeconomic development status, 1990\u20132019. Eur. J. Prev. Cardiol. 29, 1425\u20131434 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1220_CR112","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","volume":"29","author":"L Alon","year":"2022","unstructured":"Alon, L. et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 29, 938\u2013946 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1220_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088371","volume":"9","author":"S Bonapace","year":"2014","unstructured":"Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS ONE\u00a09, e88371 (2014).","journal-title":"PLoS ONE"},{"key":"1220_CR114","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1161\/ATVBAHA.112.300556","volume":"33","author":"MRP Markus","year":"2013","unstructured":"Markus, M. R. P. et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population. Arterioscler. Thromb. Vasc. Biol. 33, 1690\u20131695 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1220_CR115","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/DMSO.S394414","volume":"16","author":"XH Song","year":"2023","unstructured":"Song, X. H. et al. The association between metabolic dysfunction-associated fatty liver disease and peripheral arterial disease in the Chinese population. Diabetes Metab. Syndr. Obes. 16, 373\u2013384 (2023).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"1220_CR116","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1210\/jc.2012-3093","volume":"98","author":"G Targher","year":"2013","unstructured":"Targher, G. & Byrne, C. D. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J. Clin. Endocrinol. Metab. 98, 483\u2013495 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1220_CR117","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/imj.13549","volume":"47","author":"Y Zou","year":"2017","unstructured":"Zou, Y. et al. Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes. Intern. Med. J. 47, 1147\u20131153 (2017).","journal-title":"Intern. Med. J."},{"key":"1220_CR118","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S1473-3099(20)30136-5","volume":"20","author":"M Shahmanesh","year":"2020","unstructured":"Shahmanesh, M. et al. From the micro to the macro to improve health: microorganism ecology and society in teaching infectious disease epidemiology. Lancet Infect. Dis. 20, e142\u2013e147 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1220_CR119","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fmed.2014.00004","volume":"1","author":"V Ghevariya","year":"2014","unstructured":"Ghevariya, V. et al. Knowing what\u2019s out there: awareness of non-alcoholic fatty liver disease. Front. Med. 1, 4 (2014).","journal-title":"Front. Med."},{"key":"1220_CR120","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60\u201378 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR121","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/liv.15951","volume":"44","author":"CJ Kopka","year":"2024","unstructured":"Kopka, C. J., Pugliese, N., Brennan, P. N. & Lazarus, J. V. We must address the MASLD awareness gap, improve educational quality and prepare for the digitally quantified self. Liver Int. 44, 2099\u20132101 (2024).","journal-title":"Liver Int."},{"key":"1220_CR122","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14799","volume":"39","author":"L Gracen","year":"2022","unstructured":"Gracen, L. et al. An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. Diabet. Med. 39, e14799 (2022).","journal-title":"Diabet. Med."},{"key":"1220_CR123","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ueg2.12445","volume":"11","author":"S Driessen","year":"2023","unstructured":"Driessen, S. et al. A global survey of health care workers\u2019 awareness of non-alcoholic fatty liver disease: the AwareNASH survey. U Eur. Gastroenterol. J. 11, 654\u2013662 (2023).","journal-title":"U Eur. Gastroenterol. J."},{"key":"1220_CR124","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1665-2681(19)31317-1","volume":"12","author":"A Said","year":"2013","unstructured":"Said, A., Gagovic, V., Malecki, K., Givens, M. L. & Nieto, F. J. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann. Hepatol. 12, 758\u2013765 (2013).","journal-title":"Ann. Hepatol."},{"key":"1220_CR125","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cld.2015.10.006","volume":"20","author":"V Patel","year":"2016","unstructured":"Patel, V., Sanyal, A. J. & Sterling, R. Clinical presentation and patient evaluation in nonalcoholic fatty liver disease. Clin. Liver Dis. 20, 277\u2013292 (2016).","journal-title":"Clin. Liver Dis."},{"key":"1220_CR126","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett, D. K. et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation 140, e596\u2013e646 (2019).","journal-title":"Circulation"},{"key":"1220_CR127","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eprac.2022.03.016","volume":"28","author":"J Quek","year":"2022","unstructured":"Quek, J. et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. a meta-analysis and systematic review of 12,620,736 individuals. Endocr. Pract. 28, 667\u2013672 (2022).","journal-title":"Endocr. Pract."},{"key":"1220_CR128","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2023.25115","volume":"331","author":"H Larkin","year":"2024","unstructured":"Larkin, H. What to know about PREVENT, the AHA\u2019s new cardiovascular disease risk calculator. JAMA 331, 277\u2013279 (2024).","journal-title":"JAMA"},{"key":"1220_CR129","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","volume":"76","author":"QM Anstee","year":"2022","unstructured":"Anstee, Q. M., Castera, L. & Loomba, R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J. Hepatol. 76, 1362\u20131378 (2022).","journal-title":"J. Hepatol."},{"key":"1220_CR130","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/life13040857","volume":"13","author":"L Gheorghe","year":"2023","unstructured":"Gheorghe, L. et al. Risk scores for prediction of major cardiovascular events in non-alcoholic fatty liver disease: a no man\u2019s land? Life 13, 857 (2023).","journal-title":"Life"},{"key":"1220_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel, K. & Sebastiani, G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2, 100067 (2020).","journal-title":"JHEP Rep."},{"key":"1220_CR132","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1104\u20131112 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1220_CR133","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.7150\/thno.40249","volume":"10","author":"AM Pirmoazen","year":"2020","unstructured":"Pirmoazen, A. M., Khurana, A., El Kaffas, A. & Kamaya, A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics 10, 4277\u20134289 (2020).","journal-title":"Theranostics"},{"key":"1220_CR134","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000055","volume":"7","author":"M Noureddin","year":"2023","unstructured":"Noureddin, M. et al. Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores. Hepatol. Commun. 7, e0055 (2023).","journal-title":"Hepatol. Commun."},{"key":"1220_CR135","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes & European Association for the Study of Obesity","year":"2016","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes & European Association for the Study of Obesity. EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388\u20131402 (2016).","journal-title":"J. Hepatol."},{"key":"1220_CR136","first-page":"1779","volume":"38","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S. et al. FIB-4 predicts MACE and cardiovascular mortality in patients with nonalcoholic fatty liver disease. Can. J. Cardiol. 38, 1779\u20131780 (2022).","journal-title":"Can. J. Cardiol."},{"key":"1220_CR137","doi-asserted-by":"publisher","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","volume":"117","author":"J Vieira Barbosa","year":"2022","unstructured":"Vieira Barbosa, J. et al. Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 117, 453\u2013461 (2022).","journal-title":"Am. J. Gastroenterol."},{"key":"1220_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101789","volume":"30","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M. et al. Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK). Ann. Hepatol. 30, 101789 (2025).","journal-title":"Ann. Hepatol."},{"key":"1220_CR139","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740\u2013751 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"1220_CR140","doi-asserted-by":"crossref","unstructured":"EASL\u2013ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 63, 237\u2013264 (2015).","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"1220_CR141","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16119","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., Paik, J. M., Henry, L., Stepanova, M. & Nader, F. Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care. Liver Int. 45, e16119 (2025).","journal-title":"Liver Int."},{"key":"1220_CR142","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/liv.15730","volume":"44","author":"R Forlano","year":"2024","unstructured":"Forlano, R. et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int. 44, 61\u201371 (2024).","journal-title":"Liver Int."},{"key":"1220_CR143","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","volume":"71","author":"JF Dillon","year":"2019","unstructured":"Dillon, J. F. et al. Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care. J. Hepatol. 71, 699\u2013706 (2019).","journal-title":"J. Hepatol."},{"key":"1220_CR144","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12072-024-10661-x","volume":"18","author":"WK Chan","year":"2024","unstructured":"Chan, W. K., Wong, V. W., Adams, L. A. & Nguyen, M. H. MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD. Hepatol. Int. 18, 909\u2013921 (2024).","journal-title":"Hepatol. Int."},{"key":"1220_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2022.100335","volume":"10","author":"ND Wong","year":"2022","unstructured":"Wong, N. D. et al. Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement. Am. J. Prev. Cardiol. 10, 100335 (2022).","journal-title":"Am. J. Prev. Cardiol."},{"key":"1220_CR146","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.03.004","volume":"122","author":"NA Schuster","year":"2020","unstructured":"Schuster, N. A., Hoogendijk, E. O., Kok, A. A. L., Twisk, J. W. R. & Heymans, M. W. Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis. J. Clin. Epidemiol. 122, 42\u201348 (2020).","journal-title":"J. Clin. Epidemiol."},{"key":"1220_CR147","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ije\/dyab116","volume":"51","author":"H Cooper","year":"2022","unstructured":"Cooper, H., Wells, S. & Mehta, S. Are competing-risk models superior to standard Cox models for predicting cardiovascular risk in older adults? analysis of a whole-of-country primary prevention cohort aged \u226565 years. Int. J. Epidemiol. 51, 604\u2013614 (2022).","journal-title":"Int. J. Epidemiol."},{"key":"1220_CR148","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1467-789X.2004.00126.x","volume":"5","author":"D Festi","year":"2004","unstructured":"Festi, D. et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes. Rev. 5, 27\u201342 (2004).","journal-title":"Obes. Rev."},{"key":"1220_CR149","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","volume":"165","author":"JJ Wattacheril","year":"2023","unstructured":"Wattacheril, J. J., Abdelmalek, M. F., Lim, J. K. & Sanyal, A. J. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology 165, 1080\u20131088 (2023).","journal-title":"Gastroenterology"},{"key":"1220_CR150","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)31561-0","volume":"396","author":"F Mauvais-Jarvis","year":"2020","unstructured":"Mauvais-Jarvis, F. et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 396, 565\u2013582 (2020).","journal-title":"Lancet"},{"key":"1220_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100759","volume":"3","author":"TA Pearson","year":"2024","unstructured":"Pearson, T. A. et al. The science of precision prevention. JACC Adv. 3, 100759 (2024).","journal-title":"JACC Adv."},{"key":"1220_CR152","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41575-023-00880-2","volume":"21","author":"N Stefan","year":"2024","unstructured":"Stefan, N., Lonardo, A. & Targher, G. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases. Nat. Rev. Gastroenterol. Hepatol. 21, 136\u2013137 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR153","first-page":"3","volume":"1","author":"A Lonardo","year":"2021","unstructured":"Lonardo, A., Byrne, C. D. & Targher, G. Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going? Metab. Target Organ Damage 1, 3 (2021).","journal-title":"Metab. Target Organ Damage"},{"key":"1220_CR154","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2010.02.034","volume":"53","author":"S Romeo","year":"2010","unstructured":"Romeo, S. et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J. Hepatol. 53, 335\u2013338 (2010).","journal-title":"J. Hepatol."},{"key":"1220_CR155","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3109\/00365521.2016.1161066","volume":"51","author":"U Vespasiani-Gentilucci","year":"2016","unstructured":"Vespasiani-Gentilucci, U. et al. The PNPLA3 rs738409 C>G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand. J. Gastroenterol. 51, 967\u2013973 (2016).","journal-title":"Scand. J. Gastroenterol."},{"key":"1220_CR156","doi-asserted-by":"publisher","DOI":"10.20517\/mtod.2023.24","volume":"3","author":"A Mantovani","year":"2023","unstructured":"Mantovani, A. & Targher, G. PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease? Metab. Target Organ Damage 3, 18 (2023).","journal-title":"Metab. Target Organ Damage"},{"key":"1220_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102085","volume":"6","author":"W De Nardo","year":"2025","unstructured":"De Nardo, W. et al. Integrated liver-secreted and plasma proteomics identify a predictive model that stratifies MASH. Cell Rep. Med. 6, 102085 (2025).","journal-title":"Cell Rep. Med."},{"key":"1220_CR158","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","volume":"22","author":"S Sookoian","year":"2024","unstructured":"Sookoian, S., Rotman, Y. & Valenti, L. Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update. Clin. Gastroenterol. Hepatol. 22, 2177\u20132187.e2173 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1220_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.103797","volume":"35","author":"R Dong","year":"2025","unstructured":"Dong, R. et al. Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease. Nutr. Metab. Cardiovasc. Dis. 35, 103797 (2025).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1220_CR160","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S2213-8587(23)00086-4","volume":"11","author":"N Stefan","year":"2023","unstructured":"Stefan, N. & Schulze, M. B. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol. 11, 426\u2013440 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1220_CR161","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cpcardiol.2018.06.001","volume":"43","author":"R Arena","year":"2018","unstructured":"Arena, R. et al. Applying precision medicine to healthy living for the prevention and treatment of cardiovascular disease. Curr. Probl. Cardiol. 43, 448\u2013483 (2018).","journal-title":"Curr. Probl. Cardiol."},{"key":"1220_CR162","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41591-024-03033-3","volume":"30","author":"SS Lim","year":"2024","unstructured":"Lim, S. S. et al. Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist. Nat. Med. 30, 1874\u20131881 (2024).","journal-title":"Nat. Med."},{"key":"1220_CR163","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hep4.1673","volume":"5","author":"JM Paik","year":"2021","unstructured":"Paik, J. M. et al. The growing burden of disability related to chronic liver disease in the United States: data from the Global Burden of Disease Study 2007\u20132017. Hepatol. Commun. 5, 749\u2013759 (2021).","journal-title":"Hepatol. Commun."},{"key":"1220_CR164","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"GBD 2017 Cirrhosis Collaborators","year":"2020","unstructured":"GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 245\u2013266 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1220_CR165","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.3390\/ijerph18168801","volume":"18","author":"C Borrell","year":"2021","unstructured":"Borrell, C. et al. Socioeconomic inequalities in chronic liver diseases and cirrhosis mortality in European urban areas before and after the onset of the 2008 economic recession. Int. J. Environ. Res. Public Health 18, 8801 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1220_CR166","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.cgh.2020.08.047","volume":"19","author":"W Li","year":"2021","unstructured":"Li, W. et al. Socioeconomic factors associated with liver-related mortality from 1985 to 2015 in 36 developed countries. Clin. Gastroenterol. Hepatol. 19, 1698\u20131707.e1613 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1220_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100172","volume":"8","author":"G Askgaard","year":"2021","unstructured":"Askgaard, G. et al. Socioeconomic inequalities in the incidence of alcohol-related liver disease: a nationwide Danish study. Lancet Reg. Health Eur. 8, 100172 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"1220_CR168","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/hep.31605","volume":"73","author":"A Kardashian","year":"2021","unstructured":"Kardashian, A., Wilder, J., Terrault, N. A. & Price, J. C. Addressing social determinants of liver disease during the COVID-19 pandemic and beyond: a call to action. Hepatology 73, 811\u2013820 (2021).","journal-title":"Hepatology"},{"key":"1220_CR169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263913","volume":"17","author":"L Tran","year":"2022","unstructured":"Tran, L., Jung, J., Feldman, R. & Riley, T. 3rd Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries. PLoS ONE 17, e0263913 (2022).","journal-title":"PLoS ONE"},{"key":"1220_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.741490","volume":"10","author":"W Lu","year":"2022","unstructured":"Lu, W. et al. Association Between environmental and socioeconomic risk factors and hepatocellular carcinoma: a meta-analysis. Front. Public Health 10, 741490 (2022).","journal-title":"Front. Public Health"},{"key":"1220_CR171","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/hep4.1831","volume":"6","author":"AM Giammarino","year":"2022","unstructured":"Giammarino, A. M. et al. Community socioeconomic deprivation predicts nonalcoholic steatohepatitis. Hepatol. Commun. 6, 550\u2013560 (2022).","journal-title":"Hepatol. Commun."},{"key":"1220_CR172","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/apt.17631","volume":"58","author":"VL Chen","year":"2023","unstructured":"Chen, V. L., Song, M. W., Suresh, D., Wadhwani, S. I. & Perumalswami, P. Effects of social determinants of health on mortality and incident liver-related events and cardiovascular disease in steatotic liver disease. Aliment. Pharmacol. Ther. 58, 537\u2013545 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1220_CR173","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","volume":"16","author":"NE Rich","year":"2018","unstructured":"Rich, N. E. et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 16, 198\u2013210.e192 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1220_CR174","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.01.016","volume":"77","author":"D Marti-Aguado","year":"2022","unstructured":"Marti-Aguado, D., Clemente-Sanchez, A. & Bataller, R. Cigarette smoking and liver diseases. J. Hepatol. 77, 191\u2013205 (2022).","journal-title":"J. Hepatol."},{"key":"1220_CR175","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M., Zelber-Sagi, S., Henry, L. & Gerber, L. H. Lifestyle interventions in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 708\u2013722 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100263","volume":"3","author":"CV Schneider","year":"2021","unstructured":"Schneider, C. V., Zandvakili, I., Thaiss, C. A. & Schneider, K. M. Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort. JHEP Rep. 3, 100263 (2021).","journal-title":"JHEP Rep."},{"key":"1220_CR177","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ypmed.2015.07.003","volume":"81","author":"N Noble","year":"2015","unstructured":"Noble, N., Paul, C., Turon, H. & Oldmeadow, C. Which modifiable health risk behaviours are related? A systematic review of the clustering of smoking, nutrition, alcohol and physical activity (\u2018SNAP\u2019) health risk factors. Prev. Med. 81, 16\u201341 (2015).","journal-title":"Prev. Med."},{"key":"1220_CR178","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","volume":"78","author":"F \u00c5berg","year":"2023","unstructured":"\u00c5berg, F., Byrne, C. D., Pirola, C. J., M\u00e4nnist\u00f6, V. & Sookoian, S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J. Hepatol. 78, 191\u2013206 (2023).","journal-title":"J. Hepatol."},{"key":"1220_CR179","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen, T. H. et al. The EASL\u2013Lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61\u2013116 (2022).","journal-title":"Lancet"},{"key":"1220_CR180","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/ijerph14111366","volume":"14","author":"K Cooksey-Stowers","year":"2017","unstructured":"Cooksey-Stowers, K., Schwartz, M. B. & Brownell, K. D. Food swamps predict obesity rates better than food deserts in the United States. Int. J. Environ. Res. Public Health 14, 1366 (2017).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1220_CR181","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3945\/ajcn.115.120022","volume":"103","author":"EJ Boyland","year":"2016","unstructured":"Boyland, E. J. et al. Advertising as a cue to consume: a systematic review and meta-analysis of the effects of acute exposure to unhealthy food and nonalcoholic beverage advertising on intake in children and adults. Am. J. Clin. Nutr. 103, 519\u2013533 (2016).","journal-title":"Am. J. Clin. Nutr."},{"key":"1220_CR182","doi-asserted-by":"publisher","first-page":"g1464","DOI":"10.1136\/bmj.g1464","volume":"348","author":"T Burgoine","year":"2014","unstructured":"Burgoine, T., Forouhi, N., Griffin, S., Wareham, N. & Monsivais, P. Associations between exposure to takeaway food outlets, takeaway food consumption, and body weight in Cambridgeshire, UK: population based, cross sectional study. BMJ 348, g1464 (2014).","journal-title":"BMJ"},{"key":"1220_CR183","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jhep.2021.06.045","volume":"75","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m, H. et al. Maternal obesity increases the risk and severity of NAFLD in offspring. J. Hepatol. 75, 1042\u20131048 (2021).","journal-title":"J. Hepatol."},{"key":"1220_CR184","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jpeds.2021.03.014","volume":"234","author":"W Perng","year":"2021","unstructured":"Perng, W. et al. Pre- and perinatal correlates of ideal cardiovascular health during early childhood: a prospective analysis in the Healthy Start Study. J. Pediatr. 234, 187\u2013194 (2021).","journal-title":"J. Pediatr."},{"key":"1220_CR185","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/hep.32207","volume":"75","author":"E Vilar-Gomez","year":"2022","unstructured":"Vilar-Gomez, E. et al. High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology 75, 1491\u20131506 (2022).","journal-title":"Hepatology"},{"key":"1220_CR186","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20517\/mtod.2023.45","volume":"4","author":"R Gulati","year":"2024","unstructured":"Gulati, R., Moylan, C. A., Wilder, J. & Wegermann, K. Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease. Metab. Target Organ Damage 4, 9 (2024).","journal-title":"Metab. Target Organ Damage"},{"key":"1220_CR187","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/nu15153464","volume":"15","author":"K Norris","year":"2023","unstructured":"Norris, K., Jilcott Pitts, S., Reis, H. & Haynes-Maslow, L. A systematic literature review of nutrition interventions implemented to address food insecurity as a social determinant of health. Nutrients 15, 3464 (2023).","journal-title":"Nutrients"},{"key":"1220_CR188","unstructured":"Discussion paper on the development of an implementation roadmap 2023\u20132030 for the WHO Global Action Plan for the prevention and control of NCDs. World Health Organization https:\/\/www.who.int\/publications\/m\/item\/implementation-roadmap-2023-2030-for-the-who-global-action-plan-for-the-prevention-and-control-of-ncds-2023-2030 (2021)."},{"key":"1220_CR189","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","volume":"21","author":"S Zelber-Sagi","year":"2024","unstructured":"Zelber-Sagi, S. et al. Food inequity and insecurity and MASLD: burden, challenges, and interventions. Nat. Rev. Gastroenterol. Hepatol. 21, 668\u2013686 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.eatbeh.2023.101709","volume":"49","author":"JA Kosmas","year":"2023","unstructured":"Kosmas, J. A., Wildes, J. E., Graham, A. K. & O\u2019Connor, S. M. The role of stress in the association among food insecurity, eating disorder pathology, and binge eating-related appetitive traits. Eat. Behav. 49, 101709 (2023).","journal-title":"Eat. Behav."},{"key":"1220_CR191","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/HEP.0000000000000361","volume":"78","author":"JV Lazarus","year":"2023","unstructured":"Lazarus, J. V. et al. The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories. Hepatology 78, 911\u2013928 (2023).","journal-title":"Hepatology"},{"key":"1220_CR192","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/hep.32743","volume":"77","author":"A Kardashian","year":"2023","unstructured":"Kardashian, A., Serper, M., Terrault, N. & Nephew, L. D. Health disparities in chronic liver disease. Hepatology 77, 1382\u20131403 (2023).","journal-title":"Hepatology"},{"key":"1220_CR193","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1370\/afm.2275","volume":"16","author":"R Gold","year":"2018","unstructured":"Gold, R. et al. Adoption of social determinants of health EHR tools by community health centers. Ann. Fam. Med. 16, 399\u2013407 (2018).","journal-title":"Ann. Fam. Med."},{"key":"1220_CR194","doi-asserted-by":"publisher","unstructured":"Ivancovsky Wajcman, D. et al. A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000001058 (2024).","DOI":"10.1097\/HEP.0000000000001058"},{"key":"1220_CR195","doi-asserted-by":"crossref","unstructured":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19\u00b72 million participants. Lancet 387, 1377\u20131396 (2016).","DOI":"10.1016\/S0140-6736(16)30054-X"},{"key":"1220_CR196","unstructured":"Tackling NCDs: \u2018best buys\u2019 and other recommended interventions for the prevention and control of noncommunicable diseases. World Health Organization https:\/\/www.who.int\/publications\/i\/item\/9789240091078 (2017)."},{"key":"1220_CR197","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s12571-024-01476-7","volume":"16","author":"A van den Akker","year":"2024","unstructured":"van den Akker, A. et al. Mapping actor networks in global multi-stakeholder initiatives for food system transformation. Food Security 16, 1223\u20131234 (2024).","journal-title":"Food Security"},{"key":"1220_CR198","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3945\/ajcn.2009.28826","volume":"91","author":"AM de Silva-Sanigorski","year":"2010","unstructured":"de Silva-Sanigorski, A. M. et al. Reducing obesity in early childhood: results from Romp & Chomp, an Australian community-wide intervention program. Am. J. Clin. Nutr. 91, 831\u2013840 (2010).","journal-title":"Am. J. Clin. Nutr."},{"key":"1220_CR199","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1467-789X.2011.00904.x","volume":"12","author":"L Millar","year":"2011","unstructured":"Millar, L. et al. Reduction in overweight and obesity from a 3-year community-based intervention in Australia: the \u2018It\u2019s Your Move!\u2019 project. Obes. Rev. 12, 20\u201328 (2011).","journal-title":"Obes. Rev."},{"key":"1220_CR200","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/heapro\/dan025","volume":"23","author":"AC Bell","year":"2008","unstructured":"Bell, A. C., Simmons, A., Sanigorski, A. M., Kremer, P. J. & Swinburn, B. A. Preventing childhood obesity: the Sentinel Site for Obesity Prevention in Victoria, Australia. Health Promot. Int. 23, 328\u2013336 (2008).","journal-title":"Health Promot. Int."},{"key":"1220_CR201","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.socscimed.2017.01.047","volume":"177","author":"P Baker","year":"2017","unstructured":"Baker, P., Gill, T., Friel, S., Carey, G. & Kay, A. Generating political priority for regulatory interventions targeting obesity prevention: an Australian case study. Soc. Sci. Med. 177, 141\u2013149 (2017).","journal-title":"Soc. Sci. Med."},{"key":"1220_CR202","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx, N. et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 44, 4043\u20134140 (2023).","journal-title":"Eur. Heart J."},{"key":"1220_CR203","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/a-1877-9656","volume":"42","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S., Ng, C. H., Truong, E., Noureddin, M. & Kowdley, K. V. Nonalcoholic steatohepatitis drug development pipeline: an update. Semin. Liver Dis. 42, 379\u2013400 (2022).","journal-title":"Semin. Liver Dis."},{"key":"1220_CR204","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11883-022-01027-5","volume":"24","author":"NWS Chew","year":"2022","unstructured":"Chew, N. W. S., Ng, C. H., Muthiah, M. D. & Sanyal, A. J. Comprehensive review and updates on holistic approach towards non-alcoholic fatty liver disease management with cardiovascular disease. Curr. Atheroscler. Rep. 24, 515\u2013532 (2022).","journal-title":"Curr. Atheroscler. Rep."},{"key":"1220_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111652","volume":"211","author":"NWS Chew","year":"2024","unstructured":"Chew, N. W. S. et al. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population. Diabetes Res. Clin. Pract. 211, 111652 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1220_CR206","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren, F. L. J. et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42, 3227\u20133337 (2021).","journal-title":"Eur. Heart J."},{"key":"1220_CR207","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12933-025-02840-3","volume":"24","author":"ASP Tang","year":"2025","unstructured":"Tang, A. S. P. et al. Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety. Cardiovasc. Diabetol. 24, 285 (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"1220_CR208","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1753944718764588","volume":"12","author":"P Lopez-Jaramillo","year":"2018","unstructured":"Lopez-Jaramillo, P. et al. Polypill: an affordable strategy for cardiovascular disease prevention in low\u2013medium-income countries. Ther. Adv. Cardiovasc. Dis. 12, 169\u2013174 (2018).","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"1220_CR209","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","volume":"53","author":"RD Feldman","year":"2009","unstructured":"Feldman, R. D. et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 53, 646\u2013653 (2009).","journal-title":"Hypertension"},{"key":"1220_CR210","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamacardio.2020.2739","volume":"5","author":"N Wang","year":"2020","unstructured":"Wang, N. et al. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH Trial. JAMA Cardiol. 5, 1219\u20131226 (2020).","journal-title":"JAMA Cardiol."},{"key":"1220_CR211","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","volume":"21","author":"LY Mak","year":"2024","unstructured":"Mak, L. Y. et al. Liver diseases and hepatocellular carcinoma in the Asia\u2013Pacific region: burden, trends, challenges and future directions. Nat. Rev. Gastroenterol. Hepatol. 21, 834\u2013851 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR212","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007264","volume":"13","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami, J., Tuttle, K. & Vaduganathan, M. Cardio\u2013renal\u2013metabolic care models: toward achieving effective interdisciplinary care. Circ. Cardiovasc. Qual. Outcomes 13, e007264 (2020).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"1220_CR213","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2468-1253(24)00310-8","volume":"10","author":"JJ Gries","year":"2025","unstructured":"Gries, J. J. et al. Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease. Lancet Gastroenterol. Hepatol. 10, 82\u201394 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1220_CR214","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2019.3796","volume":"4","author":"RB Patel","year":"2019","unstructured":"Patel, R. B., Al Rifai, M., McEvoy, J. W. & Vaduganathan, M. Implications of specialist density for diabetes care in the United States. JAMA Cardiol. 4, 1174\u20131175 (2019).","journal-title":"JAMA Cardiol."},{"key":"1220_CR215","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559\u20131569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1220_CR216","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","volume":"402","author":"M Serra-Burriel","year":"2023","unstructured":"Serra-Burriel, M. et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 402, 988\u2013996 (2023).","journal-title":"Lancet"},{"key":"1220_CR217","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke, F. et al. EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"1220_CR218","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/jfmpc.jfmpc_2225_22","volume":"12","author":"AS Bhadoria","year":"2023","unstructured":"Bhadoria, A. S. et al. Preventive hepatology: an ounce of prevention or pounds of cure to curb liver diseases. J. Fam. Med. Prim. Care 12, 419\u2013421 (2023).","journal-title":"J. Fam. Med. Prim. Care"},{"key":"1220_CR219","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/jfmpc.jfmpc_1536_23","volume":"13","author":"AS Bhadoria","year":"2024","unstructured":"Bhadoria, A. S. et al. Preventive hepatology at AIIMS Rishikesh: delivering comprehensive and integrated care for liver diseases in northern state of India. J. Fam. Med. Prim. Care 13, 28\u201335 (2024).","journal-title":"J. Fam. Med. Prim. Care"},{"key":"1220_CR220","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43856-023-00398-3","volume":"3","author":"D Ivancovsky-Wajcman","year":"2023","unstructured":"Ivancovsky-Wajcman, D. et al. Integrating social nutrition principles into the treatment of steatotic liver disease. Commun. Med. 3, 165 (2023).","journal-title":"Commun. Med."},{"key":"1220_CR221","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","volume":"79","author":"JV Lazarus","year":"2023","unstructured":"Lazarus, J. V. et al. A global research priority agenda to advance public health responses to fatty liver disease. J. Hepatol. 79, 618\u2013634 (2023).","journal-title":"J. Hepatol."},{"key":"1220_CR222","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijcard.2023.04.042","volume":"383","author":"VV Anand","year":"2023","unstructured":"Anand, V. V. et al. Socioeconomic deprivation and prognostic outcomes in acute coronary syndrome: a meta-analysis using multidimensional socioeconomic status indices. Int. J. Cardiol. 383, 140\u2013150 (2023).","journal-title":"Int. J. Cardiol."},{"key":"1220_CR223","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","volume":"18","author":"M Masoodi","year":"2021","unstructured":"Masoodi, M. et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat. Rev. Gastroenterol. Hepatol. 18, 835\u2013856 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1220_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103858","volume":"76","author":"CJ Pirola","year":"2022","unstructured":"Pirola, C. J. et al. The influence of host genetics on liver microbiome composition in patients with NAFLD. eBioMedicine 76, 103858 (2022).","journal-title":"eBioMedicine"},{"key":"1220_CR225","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Tr\u00e9po","year":"2020","unstructured":"Tr\u00e9po, E. & Valenti, L. Update on NAFLD genetics: from new variants to the clinic. J. Hepatol. 72, 1196\u20131209 (2020).","journal-title":"J. Hepatol."},{"key":"1220_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.102003","volume":"46","author":"D Sharma","year":"2022","unstructured":"Sharma, D. & Mandal, P. NAFLD: genetics and its clinical implications. Clin. Res. Hepatol. Gastroenterol. 46, 102003 (2022).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"1220_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.03.036","volume":"13","author":"MS Khan","year":"2025","unstructured":"Khan, M. S. et al. Exclusion of liver disease and underutilization of liver-specific endpoints in heart failure trials. JACC Heart Fail. 13, 102490 (2025).","journal-title":"JACC Heart Fail."},{"key":"1220_CR228","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2100\u20132132 (2024).","journal-title":"Lancet"},{"key":"1220_CR229","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0140-6736(24)00550-6","volume":"403","author":"GBD 2021 Fertility and Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 Fertility and Forecasting Collaborators. Global fertility in 204 countries and territories, 1950\u20132021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2057\u20132099 (2024).","journal-title":"Lancet"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01220-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01220-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01220-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:03:12Z","timestamp":1773925392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01220-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":229,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01220-4","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"5 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.W.S.C. has received research grant support from the NUHS Seed Fund (NUHSRO\/2022\/RO5\u2009+\u20096\/Seed-Mar\/03), the National Medical Research Council Research Training Fellowship (MH 095:003\/008-303), the National University of Singapore Yong Loo Lin School of Medicine\u2019s Academic Fellowship Scheme, the NUHS Clinician Scientist Program (NCSP2.0\/2024\/NUHS\/NCWS), the CSDU Clinician\u2013Scientist Grant, and the National Medical Research Council Research Transition Award (TA24jul-0008). M.Y.C. receives salary support from a National Medical Council Research Clinician\u2013Scientist Award \u2014 Senior Investigator Category (MOH-000280-00). M.S.K. reports fees from Bayer and Novartis. M.D.M. is a consultant on the advisory panel of or has had paid speaking engagements with Astellas, Boston Scientific, Gilead, LernaBio, Olympus Medical, Perspectum and Roche. J.B. reports consulting for Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Eli Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor and Zoll. A.J.S. is a consultant for 89Bio, Akero, Aligos, Alnylam, Amgen, AstraZeneca, Avant Sante, Boehringer-Ingelheim, Boston Pharmaceutics, Corcept, Eli Lilly, Fibronostics, Genentech, Genfit, Gilead, Hanmi, Histoindex, Intercept, LG Pharma, Madrigal, Merck, Myovant, Novo Nordisk, Path AI, Pelayo Rubio, Pfizer, Poxel, Regeneron, Salix, Surrozen and Takeda; and has received royalties from Elsevier and Wolter Kluwers; and has stock options with Durect, Inversago, Northsea, Rivus and Tiziana; and receives grant support from Akero, Boehringer-Ingelheim, Echosense, E-scopics, Hanmi, Intercept, Madrigal, Merck, Novo Nordisk and Takeda. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}